CELL:中国广东省SARS-CoV-2的基因组流行病学研究 

2020-05-01 MedSci原创 MedSci原创

2020年初,我国在人口最多的省份--广东进行了广泛的分子监测,从160万例检测中报告了1388例RNA阳性病例。

2019年全球大流行的新型冠状病毒病(COVID-19)由SARS-CoV-2感染引起,2019年12月在中国中部地区首次被报告。

2020年初,我国在人口最多的省份--广东进行了广泛的分子监测,从160万例检测中报告了1388例RNA阳性病例。

为了了解SARS-CoV-2在中国的分子流行病学和遗传多样性,研究人员利用元基因组测序和分层扩增子方法,从广东的感染者个体中生成了53个基因组。

综合流行病学和系统发育分析,研究人员发现广东有多个独立的疾病来源,尽管由于SARS-CoV-2在大流行初期的病毒遗传变异率较低,系统发育的聚类是不确定的。

该结果说明了当地传播链的时间、规模和持续时间是如何受到国家的旅行限制和广东省大规模的密集监测和干预措施的影响的。

尽管取得了这些成绩,但由于从其他国家输入的病例数量增加,广东的COVID-19监测工作仍然需要进行。

 

原始出处:

Jing Lu et al. Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China. CELL, 2020; doi: https://doi.org/10.1016/j.cell.2020.04.023

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-30 3631173
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2021-02-18 hukaixun
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-11-11 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-03 小刀医生
  6. [GetPortalCommentsPageByObjectIdResponse(id=1900141, encodeId=6224190014160, content=<a href='/topic/show?id=70674912438' target=_blank style='color:#2F92EE;'>#广东省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49124, encryptionId=70674912438, topicName=广东省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sat May 30 07:39:31 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937916, encodeId=2c73193e9165f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Feb 18 02:39:31 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871720, encodeId=3ad818e172030, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 18 11:39:31 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962014, encodeId=9d551962014d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 11 19:39:31 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321180, encodeId=2c2113211807e, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411363, encodeId=ae73141136349, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 03 10:39:31 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-03 xugumin

相关资讯

NEJM:重磅!雷地西韦治疗重症Covid-19患者临床结果公布

最近,研究人员为因感染SARS-CoV-2引起的Covid-19的住院患者提供了remdesivir。

空气污染恐增新冠肺炎致死率!

全球每年有700万人因空气污染而死,空气污染与新冠肺炎又有什么关系?

OBESITY:新冠疫情或导致儿童肥胖大流行

尽管减轻其直接影响是一个优先事项,但研究人员提醒人们注意这一流行病对儿童健康的长期影响。

CELL:开发CRISPR技术抗击新冠病毒和流感

目前,SARS-CoV-2病毒正在引起全球冠状病毒病(COVID-19)的大流行,人们急切需要有效的对抗病毒的方法,这些方法可以针对没有有效的疫苗或药物的新兴病毒。

新型冠状病毒治疗药物和疫苗研发的新近进展

冠状病毒治疗最终只有靠药物和疫苗。据中国工程院院士王军志介绍,国内新冠疫苗研发从五大技术方向推进,包括灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗。其中,第一批确定

NATURE:COVID-2019年住院患者的病毒学评估报告 

最近,研究人员对9例病例进行了详细的病毒学分析,提供了上呼吸道组织中病毒复制活跃的证据。